Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
“A population of CML stem cells survives despite the inhibition of oncogenic kinase activity (Corbin et al., 2011), and it had been postulated they depend on kinase-independent roles of BCR-Abl for survival.”
Stem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E. (2017) · Nature Medicine · doi:10.1038/nm.4399 · Cited by 546
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
“Comparison of Responses and Resistance to TKIs in Chronic-Phase CML At present, five inhibitors of BCR-ABL1 have been granted FDA approval for the treatment of chronic-phase CML (Figure 3; Table 1).”
BackgroundInfluentialSelf-citationChronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
“These data have recently been strengthened by a carefully conducted study which concluded that primary CML stem cells are insensitive to imatinib despite inhibition of Bcr-Abl.(25) Similarly, in transgenic mice multiple rounds of induction and reversion of BcrAbl are possible(2,8), suggesting long-term persistence of…”
BackgroundInfluentialDomingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416
“A number of studies have shown that tumor-initiating cells (T-ICs) may preferentially survive exposure to chemotherapy, providing an attractive rationale for relapse following initial tumor shrinkage with standard therapy (Corbin et al., 2011; Ishikawa et al., 2007; Lonardo et al., 2011; Todaro et al., 2007; Yu et al.…”
BackgroundResultLi, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
“Primitive, quiescent CML LSC are resistant to apoptosis following TKI treatment despite effective inhibition of BCR-ABL kinase activity (Holtz et al., 2005; Corbin et al., 2011), the mechanisms for which are not well understood.”
BackgroundInfluentialProteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
“But lifelong drug administration is required due to the persistent CML stem cells that rely on BCR-ABL’s kinase-independent function for survival [171, 209].”
BackgroundThe leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Zhang, B., Ho, Y. W., Huang, Q., Maeda, T., Lin, A., Lee, S.-U., Hair, A., Holyoake, T. L., Huettner, C., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.018 · Cited by 348
“However, TKI are less effective in targeting CML stem cells compared to more mature leukemia cells (Corbin et al., 2011; Graham et al., 2002; Holtz et al., 2002).”
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
“A recent study suggests an alternative scenario wherein CML-LSCs are not killed by TKIs as other CML cells because they are actually insensitive to BCR/ABL inhibition (Corbin et al., 2011).”
BackgroundDual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Rea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Gardembas, M., Coiteux, V., Guillerm, G., Legros, L., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742205 · Cited by 317
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
“These conclusions were further supported by others who used imatinib to fully inhibit BCR-ABL1 kinase activity in both LSCs and quiescent cells.(55) Taken together, these studies concluded that CML LSCs were not “oncogene-addicted” and that targeting of BCR-ABL1 kinase activity alone would not eliminate them.”
ResultPushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Self-citationErosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., Saliba, J., Massonnet, G., Beressi, J.-P., Verhoeyen, E., Raggueneau, V., Maneglier, B., et al. (2015) · Nature · doi:10.1038/nature15248 · Cited by 272
Biomarkers for personalized oncology: recent advances and future challenges
Kalia, M. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.027 · Cited by 265
“Even though TK inhibitor therapy for CML has been shown to be generally successful [10], the disease is still detectable in spite of treatment [14] and CML leukemic stem cells have been shown to be resistant to TK inhibitor therapy [15].”
BackgroundZhang, B., Li, M., McDonald, T., Holyoake, T. L., Moon, R. T., Campana, D., Shultz, L., & Bhatia, R. (2013) · Blood · doi:10.1182/blood-2012-02-412890 · Cited by 264
Cancer stem cell plasticity and tumor hierarchy
Cabrera, M. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.27 · Cited by 252
The concept of treatment-free remission in chronic myeloid leukemia
Saußele, S., Richter, J., Hochhaus, A., & Mahon, F.-X. (2016) · Leukemia · doi:10.1038/leu.2016.115 · Cited by 247
The Philadelphia chromosome in leukemogenesis
Kang, Z.-J., Liu, Y.-F., Xu, L.-Z., Long, Z.-J., Huang, D., Yang, Y., Liu, B., Feng, J.-X., Pan, Y.-J., Yan, J.-S., et al. (2016) · Chinese Journal of Cancer · doi:10.1186/s40880-016-0108-0 · Cited by 233
“In brief, a quiescent population of leukemia stem cells with or without BCR-ABL1 kinase domain mutations is responsible for drug resistance [11].”
BackgroundEide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Self-citationChu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245
Heidel, F. H., Bullinger, L., Feng, Z., Wang, Z., Neff, T. A., Stein, L., Kalaitzidis, D., Lane, S. W., & Armstrong, S. A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.017 · Cited by 225
“LSCs in CML share immunophenotypic features with normal HSCs, reside in the BM and are resitant to IM treatment, despite inhibition of BCR-ABL (Corbin et al., 2010; Hu et al., 2009).”
BackgroundPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G., Dorrance, A. M., Paisie, C. A., Eiring, A. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68951 · Cited by 221
“The notion that TKIs do not kill quiescent CML HSCs (5) because BCR-ABL1 activity is dispensable for their survival (7, 8) suggests that other aberrantly regulated signals control leukemic stem cell persistence (5, 33–35).”
BackgroundSelf-citationNatural course and biology of CML
Chereda, B., & Melo, J. V. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2325-z · Cited by 220
“They showed that potent TKIs failed to wipeout CML-LSCs, that the bone marrow environment may offer sanctuary against TKIs and that withdrawal of TKIs leads to reconstitution of leukaemic expansion [100, 101].”
BackgroundDual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225
“network components (shown as bar plots) in the context of quiescent and primitive CML cells; data shown in each panel (L-R) are (1) CD34+ protein log2 ratios; (2) CD34+HstloPylo transcript logFC (E-MTAB-2508); (3) CD34+HstloPylo transcript logFC (GSE24739); (4) CD34+CD38− logFC (E-MTAB-2581); and (5) Lin−CD34+CD38−CD9…”
BackgroundMethodDipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., et al. (2014) · Blood · doi:10.1182/blood-2013-10-536078 · Cited by 223
“Nevertheless, in most patients, imatinib is unable to eradicate the disease, a phenomenon that has been explained by intrinsic and acquired drug resistance in residual leukemic SC (LSC).(6-11) Whereas intrinsic resistance is common to most or all LSC, acquired resistance results from additional (subclone-specific) les…”
BackgroundInfluentialTargeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1236 · Cited by 212
“18 475 in the progenitors, only a minor induction of apoptosis was observed in CML stem cells, adding to the growing body of evidence that CML stem cells are not dependent on BCR-ABL1 kinase activity for survival (3,5,39-41).”
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
“The goal was the design of a PROTAC capable of degrading the oncoprotein BCR/Abl, with the hope that BCR/Abl degradation would possibly eliminate kinase-independent functions of the protein (65, 66).”
BackgroundChomel, J.-C., Bonnet, M.-L., Sorel, N., Bertrand, A., Meunier, M.-C., Fichelson, S., Melkus, M., Bennaceur-Griscelli, A., Guilhot, F., & Turhan, A. G. (2011) · Blood · doi:10.1182/blood-2011-02-335497 · Cited by 197
Goff, D. J., Recart, A. C., Sadarangani, A., Chun, H.-J., Barrett, C. L., Krajewska, M., Leu, H., Low-Marchelli, J., Ma, W., Shih, A. Y., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.011 · Cited by 201
“Although BCR-ABL-targeted tyrosine kinase inhibitors (TKIs) eradicate the bulk of BCR-ABL1expressing cells, they frequently fail to eliminate quiescent, niche-resident LSCs that drive relapse (Abe et al., 2008; Barnes and Melo, 2006; Chomel et al., 2011; Corbin et al., 2011) and blast crisis (BC) transformation after…”
InfluentialRothe, K., Lin, H., Lin, K. B. L., Leung, A., Wang, H. M., Malekesmaeili, M., Brinkman, R. R., Forrest, D. L., Gorski, S. M., & Jiang, X. (2014) · Blood · doi:10.1182/blood-2013-07-516807 · Cited by 199
Nieborowska-Skorska, M., Kopinski, P. K., Ray, R., Hoser, G., Ngaba, D., Flis, S., Cramer, K., Reddy, M. M., Koptyra, M., Penserga, T., et al. (2012) · Blood · doi:10.1182/blood-2011-10-385658 · Cited by 177
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021) · Cells · doi:10.3390/cells10010117 · Cited by 180
“While much information has been gained on the nature of CML LSC, which are independent of the function of BCR-ABL1 [39,40], their eradication has remained largely elusive and the necessity of their eradication is somewhat controversial [41]—even in view of the novel concept of treatment-free remission (TFR), as discus…”
BackgroundThe Rational Development of CD133-Targeting Immunotherapies for Glioblastoma
Vora, P., Venugopal, C., Salim, S. K., Tatari, N., Bakhshinyan, D., Singh, M., Seyfrid, M., Upreti, D., Rentas, S., Wong, N., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.008 · Cited by 188
Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence
Takeishi, S., Matsumoto, A., Onoyama, I., Naka, K., Hirao, A., & Nakayama, K. I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.026 · Cited by 178
“, 2007) and the lack of addiction to BCR-ABL in these cells (Corbin et al., 2011).”
BackgroundAgarwal, P., Isringhausen, S., Li, H., Paterson, A. J., He, J., Gomariz, Á., Nagasawa, T., Nombela-Arrieta, C., & Bhatia, R. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.02.018 · Cited by 176
“Several studies indicate that LSC resistance to TKI-treatment occurs through kinaseindependent mechanisms (Corbin et al., 2011; Hamilton et al., 2012; Perl and Carroll, 2011).”
Activation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Hurtz, C., Hatzi, K., Cerchietti, L., Braig, M., Park, E., Kim, Y.-M., Herzog, S., Ramezani-Rad, P., Jumaa, H., Müller, M. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110304 · Cited by 177
“Despite its clinical success, Imatinib fails to eradicate CML entirely (Corbin et al., 2011), and in virtually all cases residual leukemia-initiating cells (LICs) persist (Kantarjian et al.”
BackgroundSelf-citationChronic myeloid leukemia stem cells
Houshmand, M., Simonetti, G., Circosta, P., Gaidano, V., Cignetti, A., Martinelli, G., Saglio, G., & Gale, R. P. (2019) · Leukemia · doi:10.1038/s41375-019-0490-0 · Cited by 177
Walz, C., Ahmed, W., Lazarides, K., Betancur, M., Patel, N., Hennighausen, L., Zaleskas, V. M., & Van Etten, R. A. (2012) · Blood · doi:10.1182/blood-2011-12-397554 · Cited by 166
“demonstrating survival of malignant stem cells from CML patients despite effective pharmacological inhibition of STAT5 with ABL1 tyrosine kinase inhibitors.(42,43) We are currently testing whether the combination of imatinib and Stat5 deficiency can eliminate leukemic stem cells in this model.”
BackgroundCXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia
Passaro, D., Irigoyen, M., Catherinet, C., Gachet, S., Da Costa De Jesus, C., Lasgi, C., Tran Quang, C., & Ghysdael, J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.003 · Cited by 167
Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170
Self-citationMitochondrial metabolism as a potential therapeutic target in myeloid leukaemia
de Beauchamp, L., Himonas, E., & Helgason, G. V. (2022) · Leukemia · doi:10.1038/s41375-021-01416-w · Cited by 168
“Supporting this hypothesis, Ye and colleagues have shown that a subpopulation of AML and BP-CML LSCs preferentially locates in extramedullary adipose niches, and overexpresses the fatty acid transporter CD36 [84].”
BackgroundInfluentialLi, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 180
“These markers include CD24 [146], CD44 [146– 150], CD90 [151, 152], CD105 [153, 154], CD123 [155– 157], CD133 [158–163], epithelial cell adhesion molecule (EpCAM) [149], ATP-binding cassette B5 (ABCB5) [164], ATP-binding cassette G2 (ABCG2) [163, 165], cytokeratin 17 (CK-17) [166], Integrin α7 [167], Interleukin-1 rec…”
Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
“Recent evidence has demonstrated that CML-LSC persistence is secondary to their insensitivity to TKI despite effective BCR-ABL kinase inhibition, suggesting that other pathways contribute to their survival.(9,10) Identifying such pathways and trying to exploit them therapeutically is paramount to achieving CML-LSC era…”
BackgroundRea, D., Henry, G., Khaznadar, Z., Etienne, G., Guilhot, F., Nicolini, F., Guilhot, J., Rousselot, P., Huguet, F., Legros, L., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.165001 · Cited by 161
Wang, L., Hua, E., Liang, M., Ma, C., Liu, Z., Sheng, S., Liu, M., Xie, G., & Feng, W. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.07.049 · Cited by 161
Kumano, K., Arai, S., Hosoi, M., Taoka, K., Takayama, N., Otsu, M., Nagae, G., Ueda, K., Nakazaki, K., Kamikubo, Y., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367441 · Cited by 170
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154
Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., Padget, M., Irvine, D. A., Sliwinski, T., Haas, K., Lee, J., Geng, H., Roy, D., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501072 · Cited by 145
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E. M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M., Dunn, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0263 · Cited by 144
“05; one-sample t tests) when their cognate mRNA levels are downregulated (↓) or upregulated (↑; Affymetrix analysis) in each of three pairwise comparisons for 3 bioreplicate CML(1,2,3) and normal samples.”
BackgroundCorces-Zimmerman, M. R., & Majeti, R. (2014) · Leukemia · doi:10.1038/leu.2014.211 · Cited by 141
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Talpaz, M., Hehlmann, R., Quintás-Cardama, A., Mercer, J., & Cortes, J. (2013) · Leukemia · doi:10.1038/leu.2012.313 · Cited by 137
Self-citationGoussetis, D. J., Gounaris, E., Wu, E. J., Vakana, E., Sharma, B., Bogyo, M., Altman, J. K., & Platanias, L. C. (2012) · Blood · doi:10.1182/blood-2012-01-402578 · Cited by 133
Targeting hedgehog in hematologic malignancy
Irvine, D. A., & Copland, M. (2012) · Blood · doi:10.1182/blood-2011-10-383752 · Cited by 155
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Eiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A. J., et al. (2015) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 131
Self-citationXia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
“Imatinib is a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), but has poor clearance for inactive leukemia stem cells (211).”
BackgroundMa, L., Shan, Y., Bai, R., Xue, L., Eide, C. A., Ou, J., Zhu, L. J., Hutchinson, L., Cerny, J., Khoury, H. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009073 · Cited by 133
“6B show that IM-resistant human CML stem cells [(15, 16, 47–49) and see below] had substantially higher expression of PRKCH compared to human CML progenitor cells, which are IMsensitive (16, 45).”
BackgroundInfluentialSelf-citationChronic myeloid leukemia: reminiscences and dreams
Mughal, T. I., Radich, J. P., Deininger, M. W., Apperley, J. F., Hughes, T. P., Harrison, C. J., Gambacorti-Passerini, C. B., Saglio, G. N., Cortes, J. E., & Daley, G. Q. (2016) · Haematologica · doi:10.3324/haematol.2015.139337 · Cited by 145
“Regardless of the dose of imatinib, the current safety analysis of imatinib is quite impressive, with very few potentially serious long-term side-effects noted after ten years or more continuous use.83 Table 1 depicts the relative toxicities of all currently available TKIs for CML.”
BackgroundInfluentialSelf-citationRegulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression
Reavie, L., Buckley, S. M., Loizou, E., Takeishi, S., Aranda-Orgilles, B., Ndiaye-Lobry, D., Abdel-Wahab, O., Ibrahim, S., Nakayama, K. I., & Aifantis, I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.025 · Cited by 131
“An increasing body of work has suggested that disease relapse upon cessation of TKI therapy could be due to a rare population of leukemia-initiating cells (LICs) that are resistant or refractory to treatment (Bhatia et al., 2003; Corbin et al., 2011; Jankowska et al., 2009).”
BackgroundTargeting quiescent leukemic stem cells using second generation autophagy inhibitors
Baquero, P., Dawson, A., Mukhopadhyay, A., Kuntz, E. M., Mitchell, R., Olivares, O., Ianniciello, A., Scott, M. T., Dunn, K., Nicastri, M. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0252-4 · Cited by 129
Dzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 127
“Cancer CSC Markers References Cervical CD133+, CD49f+, CK-17+ [35–37] Esophageal CD44+, ALDH1+, Integrin α7+ [38,39] Kidney CD24-, CD44+, CD105+, CD133+ [40–42] Lung cancer CD44+, CD90+, CD133+, ABCG2+, ALDH+ [24,33] Colon cancer CD24+, CD44+, CD133+, EpCAM+, ALDH+ [43–46] Liver cancer CD24+, CD44+, CD90+, CD133+, ALD…”
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells
Bolton-Gillespie, E., Schemionek, M., Klein, H.-U., Flis, S., Hoser, G., Lange, T., Nieborowska-Skorska, M., Maier, J., Kerstiens, L., Koptyra, M., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466938 · Cited by 128
Mitchell, R., Hopcroft, L. E. M., Baquero, P., Allan, E. K., Hewit, K. D., James, D. T., Hamilton, G. M., Mukhopadhyay, A., O’Prey, J., Hair, A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx236 · Cited by 130
“467 JNCI J Natl Cancer Inst (2018) 110(5): djx236”
Self-citationKill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
Helgason, G. V., Karvela, M., & Holyoake, T. L. (2011) · Blood · doi:10.1182/blood-2011-01-330621 · Cited by 131
Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2575 · Cited by 124
Self-citationImmune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 140
“…effectuated by targeted drugs risk being followed by the development of progressive disease owing to the emergence or presence of drug-resistant cancer cell variants (Haber et al, 2011; Vanneman & Dranoff, 2012; Wilson et al, 2012) and/or cancer stem cells (Corbin et al, 2011; Chen et al, 2012a).”
Third-line therapy for chronic myeloid leukemia: current status and future directions
Cortes, J., & Lang, F. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01055-9 · Cited by 115
Self-citationBCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Loscocco, F., Visani, G., Galimberti, S., Curti, A., & Isidori, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00939 · Cited by 120
“Accordingly, CML-LSCs are not eliminated during imatinib therapy, meaning that they use survival signals different from BCR-ABL to survive and resist during imatinib treatment (22, 23).”
BackgroundKarvela, M., Baquero, P., Kuntz, E. M., Mukhopadhyay, A., Mitchell, R., Allan, E. K., Chan, E. Y. W., Kranc, K. R., Calabretta, B., Salomoni, P., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1162359 · Cited by 118
“It is now generally accepted that disease persistence is caused by primitive CML cells that are relatively insensitive to imatinib and other TKIs and can survive for prolonged periods of time despite complete BCR-ABL kinase inhibition.(9,10) This implies that the majority of CML patients need to continue TKI treatment…”
BackgroundLabel-retaining liver cancer cells are relatively resistant to sorafenib
Xin, H.-W., Ambe, C. M., Hari, D. M., Wiegand, G. W., Miller, T. C., Chen, J., Anderson, A. J., Ray, S., Mullinax, J. E., Koizumi, T., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303261 · Cited by 111
“Kuen-Feng Chen et al 22 reported that resistance to sorafenib in HuH-7 and Sk-Hep-1 is mediated via activation of AKT.”
BackgroundBocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00194 · Cited by 108
Gu, Y., Chen, T., Meng, Z., Gan, Y., Xu, X., Lou, G., Li, H., Gan, X., Zhou, H., Tang, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-434894 · Cited by 115
Targeting the canonical Wnt/β‐catenin pathway in hematological malignancies
Ashihara, E., Takada, T., & Maekawa, T. (2015) · Cancer Science · doi:10.1111/cas.12655 · Cited by 107
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Self-citationLaperrousaz, B., Jeanpierre, S., Sagorny, K., Voeltzel, T., Ramas, S., Kaniewski, B., Ffrench, M., Salesse, S., Nicolini, F. E., & Maguer‐Satta, V. (2013) · Blood · doi:10.1182/blood-2013-05-501460 · Cited by 106
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
Warsch, W., Walz, C., & Sexl, V. (2013) · Blood · doi:10.1182/blood-2013-02-485573 · Cited by 122
“There is a general consensus that TKIs inhibit BCR-ABL1 activity in primitive lineage CD34(1)CD38(2) cells.(100,101) In contrast to progenitor cells, CML stem cells are able to survive in vitro for prolonged periods of time despite complete oncogene inactivation.”
BackgroundBavaro, L., Martelli, M., Cavo, M., & Soverini, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246141 · Cited by 117
Traer, E. A., MacKenzie, R. J., Snead, J. L., Agarwal, A., Eiring, A. M., O’Hare, T., Druker, B. J., & Deininger, M. W. (2011) · Leukemia · doi:10.1038/leu.2011.325 · Cited by 109
Self-citationFunction of oncogenes in cancer development: a changing paradigm
Vicente‐Dueñas, C., Romero-Camarero, I., Cobaleda, C., & Sánchez-García, I. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.97 · Cited by 113
“…can target with high efficiency the differentiated tumour cells of chronic myeloid leukaemia (CML) but cannot kill the BCR-ABL-expressing stem cells (Corbin et al , 2011; Chomel et al , 2011; Chu et al , 2011; Hamilton et al , 2012; Kumari et al , 2012), since it does not seem to interfere with the…”
Nievergall, E., Ramshaw, H. S., Yong, A. S. M., Biondo, M., Busfield, S. J., Vairo, G., Lopez, A. F., Hughes, T. P., White, D. L., & Hiwase, D. K. (2014) · Blood · doi:10.1182/blood-2012-12-475194 · Cited by 98
“Although first- and second-generation TKIs revolutionized the CML treatment, elimination of the disease seems elusive for themajority of patients to date likely because of residual CMLLSCs.(6,7,10) Although CD123 is a recognized specific marker for AMLCD34(1)/CD38 stem cells(18,19) and has been suggested as a CMLLSPCm…”
BackgroundRiether, C., Schürch, C. M., Flury, C., Hinterbrandner, M., Drück, L., Huguenin, A.-L., Baerlocher, G. M., Radpour, R., & Ochsenbein, A. F. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1740 · Cited by 102
“However, recent studies demonstrated that LSC survival and persistence are independent of BCR-ABL1 (3, 4), and therefore, even nextgeneration TKIs will most likely be ineffective against LSCs when used as monotherapy.”
BackgroundMicro RNA s and their relevance to ABC transporters
Haenisch, S., Werk, A. N., & Cascorbi, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12251 · Cited by 109
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Kesarwani, M., Kincaid, Z., Gomaa, A., Huber, E., Rohrabaugh, S., Siddiqui, Z., Bouso, M. F., Latif, T., Xu, M., Komurov, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4310 · Cited by 101
“Given that growth factor signaling mediates intrinsic resistance to TKI therapy in both leukemia and solid organ tumors 20–22 , we reasoned that c-FOS and DUSP1 might play a critical role in other types of kinase-driven leukemias.”
The Japan Adult Leukemia Study Group, Takahashi, N., Tauchi, T., Kitamura, K., Miyamura, K., Saburi, Y., Hatta, Y., Miyata, Y., Kobayashi, S., Usuki, K., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2334-x · Cited by 102
Antileukemic effects of AMPK activators on BCR-ABL–expressing cells
Vakana, E., Altman, J. K., Glaser, H., Donato, N. J., & Platanias, L. C. (2011) · Blood · doi:10.1182/blood-2011-01-332783 · Cited by 104
Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E. K., Bhatia, R., Copland, M., Jørgensen, H. G., & Holyoake, T. L. (2013) · Blood · doi:10.1182/blood-2013-02-485607 · Cited by 96
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition
Ng, K. P., Manjeri, A., Lee, K. L., Huang, W., Tan, S. Y., Chuah, C. T. H., Poellinger, L., & Ong, S. T. (2014) · Blood · doi:10.1182/blood-2013-07-511907 · Cited by 97
“For example, several studies have shown that primitivequiescentCMLcells are intrinsically resistant toTKIs.(10,11) Further, in patients with stable complete cytogenetic responses, the presence of BCR-ABL1-kinase domainmutations is infrequent and does not predict relapse.”
BackgroundIL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Mager, L. F., Riether, C., Schürch, C. M., Banz, Y., Wasmer, M.-H., Stuber, R., Theocharides, A. P., Li, X., Xia, Y., Saito, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77347 · Cited by 92
“The long-term outcome of CML patients has substantially improved with the use of the tyrosine kinase inhibitor imatinib, yet its efficacy may be hampered by the action of cytokines (6).”
Pellicano, F., Scott, M. T., Helgason, G. V., Hopcroft, L. E. M., Allan, E. K., Aspinall-O’Dea, M., Copland, M., Pierce, A., Huntly, B. J. P., Whetton, A. D., et al. (2014) · Stem Cells · doi:10.1002/stem.1748 · Cited by 91
Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., Paliompeis, C., Bua, M., Reid, A., Rezvani, K., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466037 · Cited by 93
Schulenburg, A., Blatt, K., Cerny‐Reiterer, S., Sadovnik, I., Herrmann, H., Marian, B., Grunt, T. W., Zielinski, C. C., & Valent, P. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0113-9 · Cited by 98
“However, even BCR/ABL TKI may not be capable of suppressing all LSC for a prolonged time period, because of stem cell resistance [11,19-23,204].”
BackgroundLeukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 102
Ladds, M. J. G. W., van Leeuwen, I. M. M., Drummond, C. J., Chu, S., Healy, A. R., Popova, G., Pastor Fernández, A., Mollick, T., Darekar, S., Sedimbi, S. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03441-3 · Cited by 89
“20 compounds activate p53 in ARN8 melanoma cells HZ00 (1) 0”
InfluentialChomel, J., & Turhan, A. G. (2011) · Oncotarget · doi:10.18632/oncotarget.333 · Cited by 96
“In addition, a recent work has shown that the survival of Ph1-positive LSCs might be independent of the BCR-ABL kinase activity [20].”
Background
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.